Metastatic renal cell carcinoma (mRCC) is one of the most treatment-resistant malignancies to conventional cytotoxic chemotherapy. Previously, systemic treatment was limited to cytokine therapy [1]. Treatment options have expanded considerably for patients with mRCC with the greater understanding of the molecular mechanisms involved [2–4]. Seven molecular targeted agents for the treatment of mRCC are now approved, with significant improvements in progression-free survival (PFS) but rarely with an impact on overall survival (OS) [5].
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2igy6k2
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Kenaf is a multipurpose crop, but a lack of genetic information hinders genetic and molecular research. In this study, we aimed t...
-
Spindle cell/pleomorphic lipoma is an uncommonly encountered benign neoplasm that is usually found in the subcutaneous tissues. Rare cases r...
-
As demonstrated by the market reactions to downgrades of various sovereign credit ratings in 2011, the credit rating agencies occupy an impo...
-
Lichtenstein intervention is currently the classic model of the regulated treatment of inguinal hernias by direct local approach. This “tens...
-
HPV vaccine now funded for boys Scoop.co.nz “Most countries who have to date introduced HPV vaccine have focused on the cervical canc...
-
Multi-organ segmentation of the head and neck area: an efficient hierarchical neural networks approach Abstract Purpose In radiation therapy...
-
ORIGINAL ARTICLES Cyclooxygenase-2 and estrogen receptor-β as possible therapeutic targets in desmoid tumors p. 47 Rasha A Khairy DOI :10....
-
Related Articles New alkylresorcinol metabolites in spot urine as biomarkers of whole grain wheat and rye intake in a Swedish middle-a...
-
2016-09-29T05-30-58Z Source: Journal of Applied Pharmaceutical Science Sadhana Nittur Holla, Meena Kumari Kamal Kishore, Mohan Babu Amber...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου